Home QL Biopharm Files for HKEX IPO with Lead Asset ZT002, a Once-Monthly GLP-1 Receptor Agonist in Phase III

QL Biopharm Files for HKEX IPO with Lead Asset ZT002, a Once-Monthly GLP-1 Receptor Agonist in Phase III

CST Updated Apr 27, 2026 09:41